What is Regeneron Pharmaceuticals's market cap?

Regeneron Pharmaceuticals (REGN) has a market capitalization of $69.5B and trades on NASDAQ.

What is Regeneron Pharmaceuticals's revenue and profitability?

Regeneron Pharmaceuticals generated $14.9B in trailing twelve-month revenue with net income of $4.4B, representing a net margin of 29.6%. Gross margin stands at 93.9%, with free cash flow of $4.1B. These figures are based on the Q1 2026 filing.

Who are Regeneron Pharmaceuticals's competitors?

Regeneron Pharmaceuticals's key competitors include Merck & Co., Amgen, Novartis, and others. These companies compete in similar markets and product categories.

Who does Regeneron Pharmaceuticals partner with?

Regeneron Pharmaceuticals's notable partners include Sanofi, Bayer, Intellia Therapeutics, and others.

What subsidiaries does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals's subsidiaries include Decibel Therapeutics.

Where is Regeneron Pharmaceuticals headquartered?

Regeneron Pharmaceuticals is headquartered in United States of America and employs approximately 13,450 people. It has been publicly traded since 1991.

Regeneron Pharmaceuticals

REGN

Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious medical conditions.

Market cap

$69.5B+17.6%

Revenue$14.9B+5.9%

Net income$4.4B-1.7%

Free cash flow$4.1B+32.6%

EPS (diluted)$41.05+4.4%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 29, 2026

Revenue$3.6BBeat by $124.9M EPS$9.47Beat by $0.56

Read the full report

Next report

Jul 30, 2026 (In 2 weeks)

Revenue estimate$3.8B

EPS estimate$10.62

Financials

Q1 2026

Income statement

See full

Revenue$3.6B+19.0%

Operating income$642.9M+8.7%

Net income$727.2M-10.1%

EPS (diluted)$6.75-7.2%

Balance sheet

See full

Cash & equivalents$3.0B-4.0%

Total debt$2.7B+0.1%

Total equity$31.4B+6.9%

Total assets$40.9B+8.9%

Cash flow

See full

Operating cash flow$1.1B+3.2%

CapEx$230.6M+0.6%

Free cash flow$848.3M+4.0%

Valuation & ratios

Valuation

See full

Market cap$69.5B+17.6%

Enterprise value$69.23B+15.8%

P/E15.7×+2.5×

P/S4.7×+0.5×

Profitability

See full

Operating margin24.3%-2.9pp

Net margin29.6%-2.3pp

FCF margin27.6%+5.5pp

Returns & leverage

See full

Return on equity14.5%-1.4pp

Debt / equity0.1×0.0×

Current ratio3.6×-1.4×

Competitors

By market cap

Johnson & Johnson$634.06B+68.9%

Merck & Co.$311.17B+53.1%

Amgen$198.61B+23.8%

Regeneron Pharmaceuticals$69.5B+17.6%

Nektar Therapeutics$2.4B+691%

Regenxbio$787.4M+78.8%

Lineage Cell Therapeutics$334.1M+44.8%

Aldeyra Therapeutics$128.5M-50.1%

By revenue growth

Amgen+9.1%

Johnson & Johnson+7.9%

Regeneron Pharmaceuticals+5.9%

Merck & Co.+2.9%

Nektar Therapeutics-36.2%

Regenxbio-44.0%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

Johnson & Johnson21.83%-2.6pp

Amgen20.96%+3.6pp

Merck & Co.13.59%-13.7pp

Nektar Therapeutics-284.18%-123pp

Regenxbio-330.23%-230pp

Profile

Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious medical conditions. The company leverages proprietary technology platforms to maintain a robust pipeline across multiple therapeutic areas, including ophthalmology, immunology, oncology, and rare diseases. Its value proposition is built on a high-productivity research engine that translates human genetics and antibody technologies into market-leading therapies.

Competitive position

A leading biotechnology innovator with a dominant position in the retinal disease market and a major global presence in immunology through strategic partnerships.

GeographiesUnited States, European Union, Japan

Customer segmentsSpecialty healthcare providers, Government healthcare programs, Private insurers

Business modelR&D-driven manufacturing, Product licensing, Collaborative commercialization

SuppliersRaw material suppliers for biologics, Specialized laboratory equipment providers, Contract research organizations (CROs), Genetic data repositories

CustomersWholesale drug distributors, Specialty pharmacies, Hospitals and clinics, Government health programs (Medicare/Medicaid)

CountryUnited States of America

Listed1991

Employees13.5K

CEOLeonard S. Schleifer

SectorHealthcare

IndustryBiotechnology

Websiteregeneron.com

FilingsSEC EDGAR

Ask your AI about Regeneron Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regeneron Pharmaceuticals's market cap?: Regeneron Pharmaceuticals (REGN) has a market capitalization of $69.5B and trades on NASDAQ.
What is Regeneron Pharmaceuticals's revenue and profitability?: Regeneron Pharmaceuticals generated $14.9B in trailing twelve-month revenue with net income of $4.4B, representing a net margin of 29.6%. Gross margin stands at 93.9%, with free cash flow of $4.1B. These figures are based on the Q1 2026 filing.
Who are Regeneron Pharmaceuticals's competitors?: Regeneron Pharmaceuticals's key competitors include Merck & Co., Amgen, Novartis, and others. These companies compete in similar markets and product categories.
Who does Regeneron Pharmaceuticals partner with?: Regeneron Pharmaceuticals's notable partners include Sanofi, Bayer, Intellia Therapeutics, and others.
What subsidiaries does Regeneron Pharmaceuticals have?: Regeneron Pharmaceuticals's subsidiaries include Decibel Therapeutics.
Where is Regeneron Pharmaceuticals headquartered?: Regeneron Pharmaceuticals is headquartered in United States of America and employs approximately 13,450 people. It has been publicly traded since 1991.